160 related articles for article (PubMed ID: 28111426)
1. Effect of Adjuvant Chemotherapy after Complete Resection for Pathologic Stage IB Lung Adenocarcinoma in High-Risk Patients as Defined by a New Recurrence Risk Scoring Model.
Jang HJ; Cho S; Kim K; Jheon S; Yang HC; Kim DK
Cancer Res Treat; 2017 Oct; 49(4):898-905. PubMed ID: 28111426
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant Chemotherapy Improves the Probability of Freedom From Recurrence in Patients With Resected Stage IB Lung Adenocarcinoma.
Hung JJ; Wu YC; Chou TY; Jeng WJ; Yeh YC; Hsu WH
Ann Thorac Surg; 2016 Apr; 101(4):1346-53. PubMed ID: 26794883
[TBL] [Abstract][Full Text] [Related]
3. A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?
Lv C; An C; Feng Q; Ma Y; Li S; Wang J; Zhang J; Wang X; Yan S; Fang J; Wang Y; Tan F; Yang Y
Clin Lung Cancer; 2015 Nov; 16(6):e173-81. PubMed ID: 25958850
[TBL] [Abstract][Full Text] [Related]
4. Role of positron emission tomography/computed tomography findings for adjuvant chemotherapy indications in stage T1b-2aN0M0 lung adenocarcinoma.
Sasada S; Miyata Y; Tsubokawa N; Mimae T; Yoshiya T; Okada M
Ann Thorac Surg; 2014 Aug; 98(2):417-22. PubMed ID: 24961842
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of adjuvant chemotherapy for lung adenocarcinoma patients with positive pleural lavage cytology findings.
Ogawa H; Uchino K; Tanaka Y; Shimizu N; Okuda Y; Tane K; Tauchi S; Nishio W; Maniwa Y; Yoshimura M
Interact Cardiovasc Thorac Surg; 2015 Jul; 21(1):34-9. PubMed ID: 25911680
[TBL] [Abstract][Full Text] [Related]
6. Identification of a low risk subgroup of stage IB lung adenocarcinoma patients.
Mizuno T; Ishii G; Nagai K; Yoshida J; Nishimura M; Mochizuki T; Kawai O; Hasebe T; Ochiai A
Lung Cancer; 2008 Dec; 62(3):302-8. PubMed ID: 18486987
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma.
Qian F; Yang W; Wang R; Xu J; Wang S; Zhang Y; Jin B; Yu K; Han B
J Thorac Cardiovasc Surg; 2018 Mar; 155(3):1227-1235.e2. PubMed ID: 29223834
[TBL] [Abstract][Full Text] [Related]
8. The prognostic role of pathologic invasive component size, excluding lepidic growth, in stage I lung adenocarcinoma.
Tsutani Y; Miyata Y; Mimae T; Kushitani K; Takeshima Y; Yoshimura M; Okada M
J Thorac Cardiovasc Surg; 2013 Sep; 146(3):580-5. PubMed ID: 23778085
[TBL] [Abstract][Full Text] [Related]
9. Extracapsular extension is a powerful prognostic factor in stage IIA-IIIA non-small cell lung cancer patients with completely resection.
Liu W; Shao Y; Guan B; Hao J; Cheng X; Ji K; Wang K
Int J Clin Exp Pathol; 2015; 8(9):11268-77. PubMed ID: 26617851
[TBL] [Abstract][Full Text] [Related]
10. Impact of adjuvant chemotherapy in stage IB non-small-cell lung cancer: an analysis of 112 consecutively treated patients.
Dediu M; Ion O; Ion R; Alexandru A; Median D; Gal C; Horvat T; Motas C; Motas N
J BUON; 2012; 17(2):317-22. PubMed ID: 22740212
[TBL] [Abstract][Full Text] [Related]
11. Radiologic Predictors for Clinical Stage IA Lung Adenocarcinoma with Ground Glass Components: A Multi-Center Study of Long-Term Outcomes.
Li Z; Ye B; Bao M; Xu B; Chen Q; Liu S; Han Y; Peng M; Lin Z; Li J; Zhu W; Lin Q; Xiong L
PLoS One; 2015; 10(9):e0136616. PubMed ID: 26339917
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
Strauss GM; Herndon JE; Maddaus MA; Johnstone DW; Johnson EA; Harpole DH; Gillenwater HH; Watson DM; Sugarbaker DJ; Schilsky RL; Vokes EE; Green MR
J Clin Oncol; 2008 Nov; 26(31):5043-51. PubMed ID: 18809614
[TBL] [Abstract][Full Text] [Related]
13. Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: The effect of postoperative adjuvant chemotherapy.
Park BJ; Cho JH; Lee JH; Shin S; Kim HK; Choi YS; Zo JI; Shim YM; Sun JM; Lee SH; Ahn JS; Ahn MJ; Park K; Kim J
Lung Cancer; 2018 Mar; 117():7-13. PubMed ID: 29496256
[TBL] [Abstract][Full Text] [Related]
14. Benefit of Adjuvant Chemotherapy After Curative Resection of Lung Metastasis in Colorectal Cancer.
Park HS; Jung M; Shin SJ; Heo SJ; Kim CG; Lee MG; Beom SH; Lee CY; Lee JG; Kim DJ; Ahn JB
Ann Surg Oncol; 2016 Mar; 23(3):928-35. PubMed ID: 26514121
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Impact of Multiple Clinicopathologic Risk Factors and c-MET Overexpression in Patients Who Have Undergone Resection of Stage IB Non-Small-Cell Lung Cancer.
Kim IH; Lee IH; Lee JE; Hong SH; Kim TJ; Lee KY; Kim YK; Kim SJ; Sung SW; Park JK; Yoo IR; Kim YS; Kim JO; Kang JH
Clin Lung Cancer; 2016 Sep; 17(5):e31-e43. PubMed ID: 26992846
[TBL] [Abstract][Full Text] [Related]
16. Impact of Lepidic Component Occupancy on Effects of Adjuvant Chemotherapy for Lung Adenocarcinoma.
Sasada S; Miyata Y; Mimae T; Mimura T; Okada M
Ann Thorac Surg; 2015 Dec; 100(6):2079-86. PubMed ID: 26298165
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma.
Koo DH; Lee JL; Kim TW; Chang HM; Ryu MH; Yook JH; Oh ST; Kim BS; Lee JS; Kang YK
Eur J Surg Oncol; 2007 Sep; 33(7):843-8. PubMed ID: 17207959
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and predictive value of the novel classification of lung adenocarcinoma in patients with stage IB.
Luo J; Huang Q; Wang R; Han B; Zhang J; Zhao H; Fang W; Luo Q; Yang J; Yang Y; Zhu L; Chen T; Cheng X; Wang Y; Zheng J; Wu H; Xia W; Chen H
J Cancer Res Clin Oncol; 2016 Sep; 142(9):2031-40. PubMed ID: 27379889
[TBL] [Abstract][Full Text] [Related]
19. Presence of podoplanin-positive cancer-associated fibroblasts in surgically resected primary lung adenocarcinoma predicts a shorter progression-free survival period in patients with recurrences who received platinum-based chemotherapy.
Koriyama H; Ishii G; Yoh K; Neri S; Morise M; Umemura S; Matsumoto S; Niho S; Ohmatsu H; Tsuboi M; Goto K; Ochiai A
J Cancer Res Clin Oncol; 2015 Jul; 141(7):1163-70. PubMed ID: 25446816
[TBL] [Abstract][Full Text] [Related]
20. C-reactive protein-albumin ratio is an independent prognostic predictor of tumor recurrence in stage IIIA-N2 lung adenocarcinoma patients.
Yamauchi Y; Safi S; Muley T; Warth A; Herth FJF; Dienemann H; Hoffmann H; Eichhorn ME
Lung Cancer; 2017 Dec; 114():62-67. PubMed ID: 29173768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
